Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cheng, S.-y. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 1: 9–18, 2000.
Yen, P. M. Physiological and molecular basis of thyroid hormone action. Physiol Rev 81: 1097–1142, 2001.
McKenna, N. J., Lanz, R. B., and O’Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocrinol Rev, 20: 321–344, 1999.
Hermanson, O., Glass, C. K., and Rosenfeld, M. G. Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab, 13: 55–60, 2002.
Levi, F, Franceschi, S., Gulie, C., Negri, E., and La Vecchia, C. Female thyroid cancer: the role of reproductive and hormonal factors in Switzerland. Oncology, 50: 309–315, 1993.
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M.J. Cancer statistics. CA Cancer J Clin, 53: 5–26, 2003.
Miki, H., Oshimo, K., Inoue, H., Morimoto, T., and Monden, Y. Sex hormone receptors in human thyroid tissues. Cancer, 66: 1759–1762, 1990.
Mizukami, Y, Michigishi, T., Nonomura, A., Hashimoto, T., Noguchi, M., and Matsubara, F. Estrogen and estrogen receptors in thyroid carcinomas. J Surg Oncol, 47: 165–169, 1991.
Yane, K., Kitahori, Y, Konishi, N., Okaichi, K., Ohnishi, T., Miyahara, H., Matsunaga, T., Lin, J. C., and Hiasa, Y. Expression of the estrogen receptor in human thyroid neoplasms. Cancer Lett, 84: 59–66, 1994.
Lewy-Trenda, I. Estrogen and progesterone receptors in neoplastic and non-neoplastic thyroid lesions. Pol J Pathol, 53: 67–72, 2002.
Yang, K., Pearson, C. E., and Samaan, N. A. Estrogen receptor and hormone responsiveness of medullary thyroid carcinoma cells in continuous culture. Cancer Res 48: 2760–2763, 1988.
Banu, K.S., Govindarajulu, P., and Aruldhas, M. M. Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. Endocr Pathol, 12: 315–327, 2001.
Manole, D., Schildknecht, B., Gosnell, B., Adams, E., and Derwahl, M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab, 86: 1072–1077, 2001.
Bur, M., Shiraki, W., and Masood, S. Estrogen and progesterone receptor detection in neoplastic and non-neoplastic thyroid tissues. Mod Pathol, 6: 469–472, 1993.
van Hoeven, K. H., Menendez-Botet, C. J., Strong, E. W, and Huvos, A.G. Estrogen and progesterone receptor content in human thyroid disease. Am J Clin Pathol, 99: 175–181, 1993.
Colomer, A., Martinez-Mas, J. V., Matias-Guiu, X., Llorens, A., Cabezas, R., Prat, J., and Garcia-Ameijeiras, A. Sex-steroid hormone receptors in human medullary thyroid carcinoma. Mod Pathol, 9: 68–72, 1996.
Bonacci, R., Pinchera, A., Fierabracci, P., Gigliotti, A., Grasso, L., and Giani, C. Relevance of estrogen and progesterone receptors enzyme immunoassay in malignant, benign and surrounding normal thyroid tissue. J Endocrinol Invest, 19: 159–164, 1996.
Metaye, T., Millet, C., Kraimps, J. L., Aubouin, B., Barbier, J., and Begon, F. Estrogen receptors and cathepsin D in human thyroid tissue. Cancer, 72: 1991–1996, 1993.
Jaklic, B. R., Rushin, J., and Ghosh, B. C. Estrogen and progesterone receptors in thyroid lesions. Ann Surg Oncol, 2: 429–434, 1995.
Verma, A. K. Retinoids in chemoprevention of cancer. J Biol Regul Homeost Agents, 17: 92–97, 2003.
Ralhan, R., and Kaur, J. Retinoids as chemopreventive agents. J Biol Regul Homeost Agents, 17: 66–91, 2003.
del Senno, L., Rossi, R., Gandini, D., Piva, R., Franceschetti, P., and degli Uberti, E. C. Retinoic acid-induced decrease of DNA synthesis and peroxidase mRNA levels in human thyroid cells expressing retinoic acid receptor alpha mRNA. Life Sci, 53: 1039–1048, 1993.
del Senno, L., Rossi, R., Franceschetti, P., delgi Uberti, E. C. Expression of all-trans-retinoic acid receptor RNA in human thyroid cells. Biochem Mol Biol Int, 33: 1107–1115, 1994.
Rochaix, P., Monteil-Onteniente, S., Rochette-Egly, C., Caratero, C., Voigt, J. J., and Jozan, S. Reduced expression of retinoic acid receptor beta protein (RAR beta) in human papillary thyroid carcinoma: immunohistochemical and western blot study. Histopathology, 33: 337–343, 1998.
Schmutzler, C., Brtko, J., Winzer, R., Jakobs, T. C., Meissner-Weigl, J., Simon, D., Goretzki, P. E., and Kohrle, J. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer, 76: 368–376, 1998.
Simon, D., Korber, C., Krausch, M., Segering, J., Groth, P., Gorges, R., Grunwald, F., Muller-Gartner, H. W., Schmutzler, C., Kohrle, J., Roher, H. D., and Reiners, C. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging, 29: 775–782, 2002.
Sap, J., Munoz, A., Damm, K., Goldberg, Y., Ghysdael, J., Leutz, A., Beug, H., and Vennstrom, B. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature, 324: 635–640, 1986.
Thormeyer, D. and Baniahmad, A. The v-erbA oncogene. Int J Mol Med, 4: 351–358, 1999.
Barlow, C., Meister, B., Lardelli, M., Lendahl, U., and Vennstrom, B. Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J, 13: 4241–4250, 1994.
Lin, K. H., Shieh, H. Y., Chen, S. L., and Hsu, H. C. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog, 26: 53–61, 1999.
Puzianowska-Kuznicka, M., Nauman, A., Madej, A., Tanski, Z., Cheng, S., Nauman, J. Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett, 155: 145–152, 2000.
Kamiya, Y., Puzianowska-Kuznicka, M., McPhie, P., Nauman, J., Cheng, S.Y., and Nauman, A. Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis, 23: 25–33, 2002.
Lin, K. H., Zhu, X. G., Shieh, H. Y, Hsu, H. C., Chen, S. T, McPhie, P., and Cheng, S. Y. Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line. Endocrinology 137: 4073–4081, 1996.
Wallin, G., Bronnegard, M., Grimelius, L., McGuire, J., and Torring, O. Expression of the thyroid hormone receptor, the oncogenes c-myc and H-ras, and the 90 kD heat shock protein in normal, hyperplastic, and neoplastic human thyroid tissue. Thyroid, 2: 307–313, 1992.
Bronnegard, M., Torring, O., Boos, J., Sylven, C., Marcus, C., and Wallin, G., 1994. Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue. J. Clin Endocrinol Metab, 79: 384–389, 1994.
Puzianowska-Kuznick, M., Krystyniak, A., Madej, A., Cheng, S.-y., and Nauman, J. Contribution of functionally impaired thyroid hormone receptor mutants to the tumorigenesis of thyroid papillary cancer. J Clin Endocrinol Metab, 87: 1120–1128, 2002.
Takano, T., Miyauchi, A., Yoshida, H., Nakata, Y., Kuma, K., Amino, N. Expression of TRbeta 1 mRNAs with functionally impaired mutations is rare in thyroid papillary carcinoma. J Clin Endocrinol Metab 88: 3447–3449, 2003.
Namba, H., Yamashita, S., Pei, H. C., Ishikawa, N., Villadolid, M. C., Tominaga, T, Kimura, H., Tsuruta, M., Yokoyama, N., and Izumi, M. Lack of PTC gene (ret proto-oncogene rearrangement) in human thyroid tumors. Endocrinol Jpn, 38: 627–632, 1991.
Zou, M., Shi, Y., and Farid, N. R. Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer, 73: 176–180, 1994.
Cinti, R., Yin, L., Ilc, K., Berger, N., Basolo, F., Cuccato, S., Giannini, R., Torre, G., Miccoli, P., Amati, P., Romeo, G., and Corvi, R. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet Cell Genet, 88: 56–61, 2000.
Chua, E. L., Wu, W. M., Tran, K. T, McCarthy, S. W., Lauer, C. S., Dubourdieu, D., Packham, N., O’Brien, C. J., Turtle, J. R., and Dong, Q. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia, J Clin Endocrinol Metab, 85: 2733–2739, 2000.
Bednarczuk, T., Hiromatsu, Y., Fukutani, T., Jazdzewski, K., Miskiewicz, P., Osikowska, M., Nauman, J. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves’ ophthalmopathy in European and Japanese populations. Eur J Endocrinol, 148: 13–18, 2003.
Kaneshige, M., Kaneshige, K., Zhu, X. G., Dace, A., Garrett, L., Carter, T. A., Kazlauskaite, R., Pankratz, D. G., Wynshaw-Boris, A., Refetoff, S., Weintraub, B., Willingham, M. C., Barlow, C., and Cheng, S.-y. Mice with a targeted mutation in the thyroid hormone β receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA, 97: 13209–13214, 2000.
Yen, P. M. Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab, 14: 327–333, 2003.
Weiss, R. E. and Refetoff, S. Resistance to thyroid hormone. Rev Endocrinol Metab Disord, 1: 97–108, 2000.
Meier, C. A., Dickstein, B. M., Ashizawa, K., McClaskey, J. H., Muchmore, P., Ransom, S. C., Merke, J. B., Hao, E. U., Usala, S. J., Bercu, B. B., Cheng, S.-y., and Weintraub, B. D. Variable transcriptional activity and ligand binding of mutant β1 3,3’,5-triiodo-L-thyronine receptors from four families with generalized resistance to thyroid hormone. Mol Endocrinol, 6: 248–258, 1992.
Suzuki, H., Willingham, M. C., and Cheng, S. Y. Mice with a mutation in the thyroid receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid, 12: 963–969, 2002.
Ying, H., Suzuki, H., Furumoto, H., Walker, R., Meltzer, P., Billingham, M. C., and Cheng, S. Y. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis, 24: 1467–1479, 2003.
Khoo, M. L., Beasley, N. J., Ezzat, S., Freeman, J. L., Asa, S. L. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab, 87: 1814–1818, 2002.
Bieche, I., Franc, B., Vidaud, D., Vidaud, M., and Lidereau, R. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid, 11: 147–152, 2001.
Heaney, A. P., Nelson, V., Fernando, M., and Horwitz, G., 2001. Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab, 86: 5025–5032, 2001.
Ishigaki, K., Namba, H., Nakashima, M., Nakayama, T., Mitsutake, N., Hayashi, T., Maeda, S., Ichinose, M., Kanematsu, T., Yamashita, S. Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab, 87: 433–440, 2002.
Holting, T., Goretzki, P. E., and Duh, Q. Y. Follicular thyroid cancer cells: a model of metastatic tumor in vitro. Oncol Rep, 8: 3–8, 2001.
Yen, P. M. and Cheng, S-y. Germline and somatic thyroid hormone receptor mutations in man. J Endocrinolo Invest, 26: (pages not known), in press, 2003.
Lin, K. H., Zhu, X. G., Hsu, H. C., Chen, S. L., Shieh, H. Y., Chen, S. T., McPhie, P., and Cheng, S. Y. Dominant negative activity of mutant thyroid hormone alpha 1 receptors from patients with hepatocellular carcinoma. Endocrinology, 138: 5308–5315, 1997.
Kimura, T., Van Keymeulen, A., Golstein, J., Fusco, A., Dumont, J. E., and Roger, P. P. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev, 22: 631–656, 2001.
Rivas, M. and Santisteban, P. TSH-activated signaling pathways in thyroid carcinogenesis. Molecular Cellular Endo Review (in press), 2003.
Fagin, J.A. Branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid (minireview). Mol Endocrinol, 16: 903–911, 2002.
Desvergne, B. and Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 20: 649–688, 1999.
Fajas, L., Webril, M. B., Auwerx, J. Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol, 27: 1–9, 2001.
Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A. M., Saladin, R., Najib, J., Laville, M., Fruchart. J. C., Deeb, S., Vidal-Puig, A., Flier, J., Briggs, M. R., Staels, B., Vidal, H., and Auwerx, J. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem, 272: 18779–18789, 1997.
Altiok, S., Xu, M., and Spiegelman, B. M. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev, 11: 1987–1998, 1997.
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA, 94: 237–241, 1997.
Elstner, E., Muller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., and Koeffler, H. P. Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA, 95: 8806–8811, 1998.
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., Spiegelman, B. M. Terminal differentiation of human breast cancer through PPAR. Mol Cell, 1: 465–470, 1998.
Brockman, J. A., Gupta, R. A., and DuBois, R. N. Activation of PPAR leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology, 115: 1049–1055, 1998.
Kuboto, T., Koshizuka, K., Williamson, I. A., Asou, H., Said, J. W., Holden, S., Miyoshi, I., Koeffler, H. P. Ligand for peroxisome proliferator activated receptor (troglitazone) has potent anti-tumor effects against human prostate cancer both in vitro and in vivo. Cancer Res, 58: 3344–3352, 1998.
Sarraf, P., Mueller, E., Jones, D., King, F.J., De Angelo, D.J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med, 4: 1046–1052, 1998.
Ohta, K., Endo, T., Haraguchi, K., Hershman, J. M., Onaya, T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86: 2170–2177, 2001.
Martelli, M. L., Iuliano, R., Le Pera, I., Sama’, I., Monaco, C., Cammarota, S., Kroll, T., Chiariotti, L., Santoro, M., Fusco, A. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab, 87: 4728–4735, 2002.
Ying, H., Suzuki, H., Zhao, L., Willingham, M. C., Meltzer, P., Cheng, S. Y. Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res, 63: 5274–5280, 2003.
Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., and Auwerx, J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J., 15: 5336–5348, 1996.
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C. J., Mueller, E., Spiegelman, B. M., and Fletcher, J. A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science, 289: 1357–1360, 2000.
Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G., and Nikiforov, Y. E. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol, 26: 1016–1023, 2002.
Marques, A. R., Espadinha, C., Catarino, A. L., Moniz, S., Pereira, T., Sobrinho, L. G., Leite, V. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 87: 3947–3952, 2002.
French, C. A., Alexander, E. K., Cibas, E. S., Nose, V., Laguette, J., Faquin, W., Garber, J., Moore, F. Jr., Fletcher, J. A., Larsen, P. R., Kroll, T. G. Genetic and biological subgroups of low-stage follicular thyroid cancers Am J Pathol, 162: 1053–1060, 2003.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
Cheng, SY. (2005). Abnormalities of Nuclear Receptors in Thyroid Cancer. In: Farid, N.R. (eds) Molecular Basis of Thyroid Cancer. Cancer Treatment and Research, vol 122. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8107-3_9
Download citation
DOI: https://doi.org/10.1007/1-4020-8107-3_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-8106-4
Online ISBN: 978-1-4020-8107-1
eBook Packages: MedicineMedicine (R0)